Exciting New Neurotoxin Recently Approved For Cosmetic Use in the United States.

I am excited to announce Xeomin, a relatively new neurotoxin on the market which was approved for cosmetic use last month (July, 2011).  With this introduction, I would like to present some helpful facts about this exciting new product:

  • The principle difference between Xeomin and Botox or Dysport is it is the only neurotoxin that contains no additives. This may mean there is a lower chance that the body will develop antibodies in response to the injectable. Theoretically, such antibodies could prevent a neurotoxin from producing the desired result.
  • Xeomin, unlike Botox and Dysport, is the only botulinum toxin that does not require refrigeration prior to reconstitution.  This feature significantly simplifies the distribution and storage of the product, thus further insuring the integrity of the substance on injection.
  • Xeomin is similar to Botox in that it is a neurotoxin that works by blocking the signals from nerve to muscle, thus paralyzing the muscles that create wrinkles.
  • Like Botox, the full effect of the product is seen after about one week and results should last about three months.
  • More than 84,000 people use Xeomin worldwide, and the United States is the 20th country to approve it for cosmetic use.

2 responses to “Exciting New Neurotoxin Recently Approved For Cosmetic Use in the United States.

  1. We apologize for the loading issues. We looked into the website and have found it works, however it could be browser problems. Try upgrading your web browser or changing web browsers.

  2. May I simply just say what a comfort to find someone who actually knows what
    they are discussing over the internet. You certainly understand how to bring
    an issue to light and make it important. A lot more
    people must look at this and understand this side of your story.
    It’s surprising you are not more popular because you most certainly have the gift.

Leave a Reply

Your email address will not be published. Required fields are marked *